Quick links
Quick links
| No. | Article Type | Article Title | Article Page |
|---|---|---|---|
| 1 | Clinical Research | Outcomes and Survival for Early-Stage Non-Small Cell Lung Cancer Following Wedge Resection or Lobectomy: A Propensity Score-Matched Analysis Using a Novel Peruvian Registry | 501 - 510 |
| 2 | Clinical Research | Impact of Postoperative Prolonged Air Leakage on Long-Term Pulmonary Function after Lobectomy for Lung Cancer | 511 - 518 |
| 3 | Clinical Research | Prediction Model of Delayed Hemothorax in Patients with Traumatic Occult Hemothorax Using a Novel Nomogram | 519 - 528 |
| 4 | Commentary | Commentary: Prediction Model of Delayed Hemothorax in Patients with Traumatic Occult Hemothorax Using a Novel Nomogram | 529 - 530 |
| 5 | Clinical Research | Ultrasound-Guided Percutaneous Tracheostomy in Cardiovascular and Thoracic Surgery of South Korea: Retrospective Evaluation of Efficacy and Safety in Critically Ill Patients | 531 - 535 |
| 6 | Clinical Research | Costs Associated with Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement in Korea | 536 - 546 |
| 7 | Case Report | Diaphragmatic Fibromatosis: A Diagnostic and Therapeutic Challenge: A Case Report and Review of the Literature | 547 - 552 |
| 8 | Historical Note | Historical Perspectives of the Korean Society for Thoracic and Cardiovascular Surgery: Yung Kyoon Lee (1921–1994), Who Performed the First Open-Heart Surgery Using a Cardiopulmonary Bypass Machine in Korea | 553 - 556 |
Split Viewer
Korean J Thorac Cardiovasc Surg 2007; 40(6): 428-434
Published online June 5, 2007
Copyright © Journal of Chest Surgery.
Jin Gu Lee, M.D.*, Kyung Young Chung, M.D.*, Inkyu Park, M.D.*, Dae Joon Kim, M.D.*, Kil Dong Kim, M.D.*, Sang Ho Cho, M.D.*
Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Recent studies have suggested that UFT may be an effective adjuvant therapy for completely resected IB (pT2N0) non-small cell lung cancer (NSCLC). We designed this study to clarify the feasibility of performing adjuvant chemotherapy with UFT for completely resected IB non-small cell lung cancer. Material and Method: We randomly assigned patients suffering with completely resected IB non-small cell lung cancer to receive either UFT 3g for 2 year or they received no treatment. All patients had to be followed until death or the cut-off date (December 31 2006). Result: From June 2002 through December 2004, 64 patients were enrolled. Thirty five patients were assigned to receive UFT (the UFT group) and 29 patients were assigned to observation (the control group). A follow-up survey on the 3 year survival rate was successfully completed for all the patients. The median follow-up time for all the patients was 32.8 months. In the UFT group, the median time of administration was 98 weeks (range: 2∼129 weeks). The rate of compliance was 88.2% at 6 months, 87.5% at 12 months, 80.6% at 18 month and 66.7% at 24 months. Seven recurrences (24.1%) occurred in the control group and six (17.1%) occurred in the UFT group (p=0.489). The three-year disease free survival rate was 71.3% for the control group and 82.0% for the UFT group (p=0.331). On the subgroup analysis, the three-year disease free survival rate for the patients with adenocacinoma was 45.0% for the control group and 75.2% for the UFT group (p=0.121). The three-year disease free survival rate for the patients with non-adenocarcinoma was 88.1% for the control group and 88.9% for the UFT group (p=0.964). Conclusion: Postoperative oral administration of UFT was well-tolerated. Adjuvant chemotherapy with UFT for completely resected pT2N0 adenocarcinoma of the lung could be expected to improve the disease free survival, but this failed to achieve statistical significance. A prospective randomized study for a large number of patients will be necessary.
Keywords: Adjuvant therapy, Lung neoplasm
Korean J Thorac Cardiovasc Surg 2007; 40(6): 428-434
Published online June 5, 2007
Copyright © Journal of Chest Surgery.
Jin Gu Lee, M.D.*, Kyung Young Chung, M.D.*, Inkyu Park, M.D.*, Dae Joon Kim, M.D.*, Kil Dong Kim, M.D.*, Sang Ho Cho, M.D.*
Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background: Recent studies have suggested that UFT may be an effective adjuvant therapy for completely resected IB (pT2N0) non-small cell lung cancer (NSCLC). We designed this study to clarify the feasibility of performing adjuvant chemotherapy with UFT for completely resected IB non-small cell lung cancer. Material and Method: We randomly assigned patients suffering with completely resected IB non-small cell lung cancer to receive either UFT 3g for 2 year or they received no treatment. All patients had to be followed until death or the cut-off date (December 31 2006). Result: From June 2002 through December 2004, 64 patients were enrolled. Thirty five patients were assigned to receive UFT (the UFT group) and 29 patients were assigned to observation (the control group). A follow-up survey on the 3 year survival rate was successfully completed for all the patients. The median follow-up time for all the patients was 32.8 months. In the UFT group, the median time of administration was 98 weeks (range: 2∼129 weeks). The rate of compliance was 88.2% at 6 months, 87.5% at 12 months, 80.6% at 18 month and 66.7% at 24 months. Seven recurrences (24.1%) occurred in the control group and six (17.1%) occurred in the UFT group (p=0.489). The three-year disease free survival rate was 71.3% for the control group and 82.0% for the UFT group (p=0.331). On the subgroup analysis, the three-year disease free survival rate for the patients with adenocacinoma was 45.0% for the control group and 75.2% for the UFT group (p=0.121). The three-year disease free survival rate for the patients with non-adenocarcinoma was 88.1% for the control group and 88.9% for the UFT group (p=0.964). Conclusion: Postoperative oral administration of UFT was well-tolerated. Adjuvant chemotherapy with UFT for completely resected pT2N0 adenocarcinoma of the lung could be expected to improve the disease free survival, but this failed to achieve statistical significance. A prospective randomized study for a large number of patients will be necessary.
Keywords: Adjuvant therapy, Lung neoplasm
2022; 55(2): 174-176
PDF
Standard view
Export citation
Share 
